# PT-141 Side Effects: What the Trials and Label Document > PT-141 side effects from the trials and FDA label: nausea (~40% long-term, the top discontinuation reason), flushing (~21%), headache (~12%), a transient blood-pressure rise, and skin/gum darkening. Cited. We put the uncomfortable numbers up front — nausea, flushing, headache, the blood-pressure signal, and skin darkening — straight from the RCTs and the label. The community field reports come after, clearly labeled and kept separate. ## The short version Here's the honest tolerability picture for **PT-141 side effects**, up front and cited. The big one is nausea — about 40% of people over long-term use felt it, and it was the leading reason participants stopped [4]. After that: flushing (warm, red skin) in about 21%, headache in about 12%, plus injection-site reactions and a stuffy nose [4]. Two safety flags matter more than frequency: a temporary rise in blood pressure (with a small drop in heart rate), which is why it's contraindicated if you have uncontrolled high blood pressure or known heart disease [6]; and, with repeated frequent dosing, darkening of skin and gums [6]. Below: the cited numbers first, then a clearly-marked box of what people report on forums (not evidence, not advice). ## The cited adverse-event profile These figures come from the trials and the FDA label — this is the evidence layer, and every number is sourced. **Nausea is the headline side effect.** In the 52-week open-label extension of RECONNECT (684 women), the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea wasn't just common — across the program it was a notable driver of people stopping treatment [4][12]. In the pivotal Phase 3 trials, nausea, flushing, and headache were again the most frequent events [3]. The reassuring part: across that long-term extension, no new safety signals emerged and the desire benefit held [4]. **The cardiovascular signal is the one to respect.** Bremelanotide causes a transient increase in blood pressure (and a transient drop in heart rate) after dosing. Ambulatory blood-pressure monitoring was used specifically to characterize this effect and inform the label [10], and an early Phase 1 study profiled the safety, tolerability, and hemodynamics [11]. Because of that signal, the US label contraindicates use in uncontrolled hypertension or known cardiovascular disease [6]. This is not a "minor" footnote — it's the reason a whole group of people shouldn't take it. **Hyperpigmentation is the melanocortin tell.** Darkening (hyperpigmentation) of the face, gums, and breasts has been reported with repeated, frequent dosing, attributed to activation of the peripheral MC1R receptor — the same receptor family the drug hits centrally for desire [6]. It's a direct consequence of the mechanism, not a contaminant. The label and the expert literature both flag it [6][12]. ## Honest efficacy-vs-tolerability framing A responsible tolerability page has to weigh the trade. The benefit is real but modest — integrated FSFI-desire +0.35 and FSDS-DAO item-13 −0.33 versus placebo [3] — and critical re-analyses argue those effects, while statistically significant, are small and worth debating on clinical meaningfulness [12]. Against that sits a roughly 40% long-term nausea rate that drove discontinuations [4]. That's the actual decision shape researchers describe: a modest desire signal on one side, a real and sometimes deal-breaking tolerability cost on the other [13]. We're not here to tip the scale — just to put both pans in plain view. One more clarifier, because it comes up constantly: PT-141 does not act through the HPG axis and does not directly raise testosterone, and it is not a PDE-5 inhibitor acting on blood vessels [1]. Misframing the mechanism leads to misframing the risks. ## What researchers commonly report (field reports, not clinical data) **Community accounts, not clinical data.** Everything in this section is unverified first-hand experience widely passed around in forums and discussion threads — not trial results, not from any journal, and not advice. No PMID backs a single line here. Nothing in this box is a dosing protocol or an encouragement to self-administer. We include it because the domain says "reviews," and a fair digest names what people say — then fences it off from the evidence above. With that fence firmly up, the recurring **PT-141 reviews** themes people describe are these. A rapid-onset "flush" — a warm, sometimes blotchy feeling spreading over the face and chest not long after a dose — is one of the most-mentioned sensations. Nausea is the other constant; people trade notes on its timing (often within the first hour or two) and on eating beforehand or adjusting when they dose to blunt it. Many describe the effect as showing up as spontaneous interest or desire rather than as a mechanical, on-demand response — which lines up with the brain-acting mechanism, though that's our editorial observation, not a measured claim. Off-label male use gets discussed anecdotally; we report that it's discussed, and repeat that the male evidence is investigational only and not approved. And one warning researchers pass around to each other: with repeated frequent dosing, people report transient skin or gum darkening — the same hyperpigmentation the label documents [6]. Read all of this as reported experience, not evidence and not advice. --- The PT-141 (bremelanotide) record drawn as a comic page printed at midnight — the one approved use, the modest desire effect, and the nausea-led tolerability cost inked loud and cited panel by panel, with the unverified field reports kept in their own yellow speech bubble; no clinic behind the page and nothing here dosed, dispensed, or sold.